TECP
NGNE icon

Trails Edge Capital Partners’s Neurogene NGNE Stock Holding History

Trails Edge Capital Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Sell
714,885
-67,902
-9% -$1.87M 3.57% 13
2026
Q1 		$15.8M Sell
782,787
-2,213
-0.3% -$42.9K 3.62% 12
2025
Q4 		$16.2M Buy
+785,000
New +$19.5M 4% 10

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trails Edge Capital Partners's NGNE Position: Q2 2026 in Review

Trails Edge Capital Partners reduced its Neurogene (NGNE) stake by 8.7% in Q2 2026, selling an estimated $1.87M and leaving 714,885 shares worth $22.5M. The position accounts for 3.57% of the portfolio, ranked #13.

Trails Edge Capital Partners first reported a position in NGNE in Q4 2025 and has held it in 3 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Trails Edge Capital Partners held 714,885 shares of Neurogene worth $22.5M as of Q2 2026.
  • Trails Edge Capital Partners sold 67,902 Neurogene shares in Q2 2026, an estimated $1.87M.
  • Neurogene made up 3.57% of Trails Edge Capital Partners's portfolio in Q2 2026, its #13 holding.
  • Trails Edge Capital Partners first reported a position in Neurogene in Q4 2025 and has held it in 3 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.